

August 7, 2012



Roy T. Tanaka Joins BioSig Technologies' Board of Directors

LOS ANGELES, CA -- (Marketwire) -- 08/07/12 -- BioSig Technologies, Inc., a medical device company developing unique clinical solutions to optimize the diagnosis and treatment of cardiac arrhythmias, today announced that Roy T. Tanaka has joined the Company's Board of Directors.

Roy T. Tanaka commented, "I am very excited to join BioSig's Board and such an innovative team. The Company's technology has promise to improve safety, efficacy and efficiency of electrophysiological procedures."

Kenneth Londoner, CEO of BioSig, added, "We are honored to welcome Roy Tanaka to our Board of Directors. His extensive experience at the helm of Biosense Webster, a worldwide leader in diagnostic and therapeutic electrophysiological devices, makes him a strong addition to our board as we establish ourselves as an innovator in the electrophysiology community."

Mr. Tanaka served as the worldwide President of Biosense Webster, Inc. for Johnson & Johnson from 2004 through 2008. He joined Biosense as the U.S. President in 1997. Previously he held a variety of senior management positions at Sorin Biomedical, Inc., including President and Chief Executive Officer, and leadership roles at CooperVision Surgical and Shiley, a division of Pfizer, Inc. He serves on the Boards of Directors of Coherex Medical, Advanced Cardiac Therapeutics, Volcano Corporation and VytronUS. Mr. Tanaka received a B.S. in Mechanical Engineering from Purdue University and an M.B.A. from Illinois Benedictine College.

About BioSig Technologies:

BioSig Technologies is a medical device company developing unique clinical solutions for the diagnosis and treatment of abnormal heart rhythms (arrhythmias). BioSig's PURE (Precise Uninterrupted Real-time evaluations of Electrograms) platform is designed to assist electrophysiologists during the termination of arrhythmias by cardiac ablation. PURE empowers electrophysiologists to make crucial clinical decisions in real time by providing information unobtainable with any other equipment presently in the electrophysiology (EP) lab. The Company is collaborating with physicians from the world-renowned Texas Cardiac Arrhythmia Institute (TCAI) in Austin, Texas.

Lora Mikolaitis
Director of Marketing
BioSig Technologies, Inc.
12424 Wilshire Blvd Suite 745

Los Angeles, CA 90025
310.820.8100
310.948.7200 cell

Source: BioSig Technologies Inc